BT8009, a bicyclic peptide conjugated to the cancer-killing toxin MMAE, showed strong anti-tumor activity across multiple cancer types in preclinical studies with potential advantages over antibody-drug conjugates in tumor penetration and tolerability.
1-2 Hour Half-LifeBT8009's bicyclic peptide clears the body rapidly via renal elimination — potentially reducing systemic toxicity compared to antibody-drug conjugates with multi-day half-lives
What the researchers found
BT8009, a bicycle toxin conjugate consisting of a Nectin-4-binding bicyclic peptide linked to MMAE, demonstrated significant antitumor activity across multiple preclinical cancer models. It showed superior or equivalent activity to an enfortumab vedotin analog. Key pharmacokinetic advantages include rapid tissue diffusion and tumor penetration due to its small size, and renal elimination with a half-life of 1-2 hours in rats and non-human primates — dramatically shorter than antibody-based approaches, which may reduce systemic toxicity exposure.
Why it matters
Antibody-drug conjugates like enfortumab vedotin work well for bladder cancer but can cause significant toxicity that forces many patients to stop treatment. BT8009's peptide-based approach offers a potential solution: the small bicyclic peptide penetrates tumors faster and clears the body quickly, potentially delivering the same cancer-killing power with fewer side effects — and across a broader range of Nectin-4-expressing cancers.
How the study worked
The researchers designed and synthesized BT8009 using a Nectin-4-targeting bicyclic peptide coupled to MMAE via a cleavable linker. They evaluated antitumor activity in multiple preclinical tumor models across various cancer indications, conducted preclinical safety studies, and characterized pharmacokinetic properties in rats and non-human primates. Activity was compared to an analog of the approved antibody-drug conjugate enfortumab vedotin.
What this study cannot tell us
All efficacy and safety data presented are from preclinical models, which may not predict human outcomes. The short half-life could require more frequent dosing. Nectin-4 expression levels vary across tumor types, and clinical efficacy beyond urothelial cancer remains to be demonstrated. The Phase 1/2 trial is ongoing and results have not yet been reported in this paper.
How to read the evidence
This is a preclinical study characterizing a novel therapeutic agent. The data across multiple tumor models and species (rat, NHP) is comprehensive for this stage of development, but clinical efficacy and safety remain to be established in the ongoing Phase 1/2 trial.
When this study was published
Published in 2022, this paper describes BT8009's preclinical development. The Phase 1/2 clinical trial was ongoing at publication, and clinical results may have become available since.
The bigger picture
Bicycle toxin conjugates represent an emerging class of peptide-drug conjugates that sit between small molecules and antibodies. They combine the targeting precision of biologics with the tumor-penetrating ability of small molecules. BT8009's entry into clinical trials marks an important milestone for this platform, and if successful, could establish bicyclic peptides as a new modality for targeted cancer therapy beyond the antibody-drug conjugate paradigm.
Questions still open
- Will BT8009's rapid tumor penetration translate to clinical superiority over enfortumab vedotin in human patients?
- Which non-urothelial cancer types with Nectin-4 expression will respond best to BT8009?
- Could the bicyclic peptide platform be adapted to target other tumor-associated antigens beyond Nectin-4?
Common questions
What is a bicycle toxin conjugate and how is it different from an antibody-drug conjugate?
Is BT8009 available for patients yet?
Read the original research
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Molecular cancer therapeutics, 21(12), 1747-1756
Citation
Rigby, Michael; Bennett, Gavin; Chen, Liuhong; Mudd, Gemma E; Harrison, Helen; Beswick, Paul J; Van Rietschoten, Katerine; Watcham, Sophie M; Scott, Heather S; Brown, Amy N; Park, Peter U; Campbell, Carly; Haines, Eric; Lahdenranta, Johanna; Skynner, Michael J; Jeffrey, Phil; Keen, Nicholas; Lee, Kevin. (2022). BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.. Molecular cancer therapeutics, 21(12), 1747-1756. https://doi.org/10.1158/1535-7163.MCT-21-0875